These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9422855)

  • 1. Dynamics of coronary thrombolysis and reocclusion.
    Becker R
    Clin Cardiol; 1997 Nov; 20(11 Suppl 3):III2-5. PubMed ID: 9422855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of reocclusion after coronary thrombolysis.
    Eisenberg PR
    Z Kardiol; 1993; 82 Suppl 2():175-8. PubMed ID: 8328198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T; Saitoh S; Asakura T; Kanke M; Owada K; Maruyama Y
    Int J Cardiol; 1993 Mar; 38(3):225-33. PubMed ID: 8463004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coronary reocclusion--an unsolved problem in thrombolytic therapy of acute myocardial infarct].
    Huber K
    Z Gesamte Inn Med; 1993; 48(6-7):316-23. PubMed ID: 8333228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet and anticoagulant use after myocardial infarction.
    Almony GT; Lefkovits J; Topol EJ
    Clin Cardiol; 1996 May; 19(5):357-65. PubMed ID: 8723593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of new antiplatelet agents as adjunctive therapies in thrombolysis.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Am J Cardiol; 1991 Jan; 67(3):12A-18A. PubMed ID: 1990781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The management of postthrombolysis patients].
    Branzi A; Melandri G; Galié N
    Cardiologia; 1991 Dec; 36(12 Suppl 1):413-9. PubMed ID: 1688159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction.
    Fuster V; Stein B; Badimon L; Chesebro JH
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):78A-84A. PubMed ID: 3057038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion.
    Becker RC
    Clin Cardiol; 1994 Jan; 17(1):3-13. PubMed ID: 8149679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis.
    LeBreton H; Topol E; Plow EF
    Cardiovasc Res; 1996 Feb; 31(2):235-6. PubMed ID: 8730399
    [No Abstract]   [Full Text] [Related]  

  • 15. Principles underlying the use of conjunctive agents with plasminogen activators.
    Shebuski RJ
    Ann N Y Acad Sci; 1992 Dec; 667():382-94. PubMed ID: 1309058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
    Yao SK; Ober JC; Ferguson JJ; Maffrand JP; Anderson HV; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1993; 106():110-9. PubMed ID: 8036734
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
    White HD; French JK; Hamer AW; Brown MA; Williams BF; Ormiston JA; Cross DB
    J Am Coll Cardiol; 1995 Jan; 25(1):218-23. PubMed ID: 7798505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin antagonists and antiplatelet agents.
    Becker RC
    Am J Cardiol; 1992 Jan; 69(2):39A-51A. PubMed ID: 1729878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.